Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.
MICs were determined for an investigational ketolide, CEM-101, and azithromycin, telithromycin, doxycycline, levofloxacin, clindamycin, and linezolid against 36 Mycoplasma pneumoniae, 5 Mycoplasma genitalium, 13 Mycoplasma hominis, 15 Mycoplasma fermentans, and 20 Ureaplasma isolates. All isolates, including two macrolide-resistant M. pneumoniae isolates, were inhibited by CEM-101 at < or = 0.5 microg/ml, making CEM-101 the most potent compound tested.
Waites
Ken B
KB
Department of Pathology, 619 19th Street South, WP 230, University of Alabama at Birmingham, Birmingham, AL 35249, USA. waiteskb@uab.edu
Crabb
D M
DM
Duffy
Lynn B
LB
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D006801:Humans; D048628:Ketolides / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009174:Mycoplasma / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D009175:Mycoplasma Infections / Q000382:microbiology; D016858:Mycoplasma fermentans / Q000187:drug effects / Q000302:isolation & purification; D045704:Mycoplasma genitalium / Q000187:drug effects / Q000302:isolation & purification; D009177:Mycoplasma pneumoniae / Q000187:drug effects; D014509:Ureaplasma / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D016869:Ureaplasma Infections / Q000382:microbiology
D000900:Anti-Bacterial Agents; D048628:Ketolides